Trimetazidine: A metabolic agent for the treatment of stable angina

European Heart Journal, Supplement

Volumn 3, Issue O, 2001, Pages 012-015

  Marzilli, M ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Medical therapy; Stable angina; Trimetazidine

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIANGINA PECTORIS AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; GLUCOSE; NITRIC ACID DERIVATIVE; PLACEBO; TRIMETAZIDINE;

AGED; ANGINA PECTORIS; BIOEQUIVALENCE; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENERGY METABOLISM; EXERCISE; FATTY ACID OXIDATION; GLUCOSE METABOLISM; HEART HEMODYNAMICS; HEMODYNAMIC MONITORING; HUMAN; MULTICENTER STUDY; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0012120372     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1520-765x(01)90149-x     Document Type: Conference Paper

References (28)

1. Management of patients with chronic stable angina at low risk for serious cardiac events
2. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris
3. The Total Ischemic Burden European Trial (TIBET)
4. Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina
5. New anti-ischemic drugs: Cytoprotective action with no primary haemodynamic effects
6. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase
7. Cardiac energetics during ischemia and the rationale for metabolic interventions
8. Optimizing cardiac energy metabolism: How can fatty acid and carbohydrate metabolism be manipulated?
9. Trimetazidine inhibits neutrophil accumulation after myocardial ischaemia and reperfusion in rabbits
10. Anti-ischemic effects of Trimetazidine: 31P-NMR spectroscopy in the isolated rat heart
11. Cardioprotective effect of trimetazidine during coronary artery graft surgery
12. Limitation of infarct size by trimetazidine
13. Infarct size in rabbits: A modified method illustrated by the effects of propra-nolol and trimetazidine
14. Improvement of long-term preservation of isolated arrested rat heart: Beneficial effect of the antiischemic agent trimetazidine
15. Myocardial protection during percutaneous transluminal coronary angioplasty: Effects of trimetazidine
16. Acute effects of trimetazidine evaluated by exercise testing
17. Clinical features of an anti-anginal drug in angina pectoris
18. The effects of trimetazidine on ergometric parameters in exercise-induced angina. Controlled multicenter double blind versus placebo study
19. Effectiveness of trimetazidine in stable effort angina due to chronic coronary insufficiency. A double-blind versus placebo study
20. Comparison of trimetazidine with nifedipine in effort angina: A double-blind crossover study
21. Trimetazidine: A new concept in the treatment of angina. Comparison with propranolol in patients with stable angina
22. Combination of trimetazidine with nifedipine in effort angina
23. Beneficial effects of trimetazidine in men with stable angina under beta-blocker treatment
24. Antianginal efficacy of the combination of trimetazidine-propranolol compared with isosorbide dinitrate-propranolol in patients with stable angina
25. Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease
26. Combination treatment with trimetazidine and diltiazem in stable angina pectoris
27. Combination treatment of stable effort angina using trimetazidine and metoprolol: Results of a randomized, double-blind, multicentre study (TRIMPOL II)
28. The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-I